Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Diabetes afflicts an increasing number of people worldwide each year. Proper blood glucose control is essential in preventing complications associated with diabetes, such as neuropathy, nephropathy and retinopathy.
Glycation is the result of a sugar molecule, such as fructose or glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is a haphazard process that impairs the functioning of biomolecules. The high levels of glucose present in diabetes meatus results in increased glycation of all proteins, including, albumin. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period.
Thus serum glycated albumin assay can be used to determine the current level of glycation of albumin, the most abundant plasma protein. Hence, the gycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the precious 2 to 4 weeks.
Scope of the Report:
Glycated albumin industry is relatively concentrated, manufacturers are mostly in the Europe, North America, Japan and China. Among them, Japan output value accounted for more than 81.90% of the total output value of global glycated albumin. Asahi Kasei Pharma is the world leading manufacturer in global glycated albumin market with the market share of 79.81% in 2015, in terms of revenue.
There are companies adding new capacities and aims at the cost and quality leadership which shall improve profitability. As the same time, companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality.
The average price of glycated albumin will fall further. The product average price declined in the past few years due to the technology development, the average price will keep this trend in the few future years due to increasing mature manufacturing technology and cost of raw materials.
The worldwide market for Glycated Albumin is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 490 million US$ in 2024, from 340 million US$ in 2019, according to a new study.
This report focuses on the Glycated Albumin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Asahi Kasei Pharma
DIAZYME
Abnova
LifeSpan
Exocell
BSBE
Medicalsystem
Maccura
Leadman
Simes Sikma
NINGBO PUREBIO
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Glycated Albumin (Human)
Glycated Albumin (Animal)
Market Segment by Applications, can be divided into
Hospitals and Clinics
Laboratories
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glycated Albumin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glycated Albumin, with price, sales, revenue and global market share of Glycated Albumin in 2017 and 2018.
Chapter 3, the Glycated Albumin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glycated Albumin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Glycated Albumin market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Glycated Albumin sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Glycation is the result of a sugar molecule, such as fructose or glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is a haphazard process that impairs the functioning of biomolecules. The high levels of glucose present in diabetes meatus results in increased glycation of all proteins, including, albumin. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period.
Thus serum glycated albumin assay can be used to determine the current level of glycation of albumin, the most abundant plasma protein. Hence, the gycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the precious 2 to 4 weeks.
Scope of the Report:
Glycated albumin industry is relatively concentrated, manufacturers are mostly in the Europe, North America, Japan and China. Among them, Japan output value accounted for more than 81.90% of the total output value of global glycated albumin. Asahi Kasei Pharma is the world leading manufacturer in global glycated albumin market with the market share of 79.81% in 2015, in terms of revenue.
There are companies adding new capacities and aims at the cost and quality leadership which shall improve profitability. As the same time, companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality.
The average price of glycated albumin will fall further. The product average price declined in the past few years due to the technology development, the average price will keep this trend in the few future years due to increasing mature manufacturing technology and cost of raw materials.
The worldwide market for Glycated Albumin is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 490 million US$ in 2024, from 340 million US$ in 2019, according to a new study.
This report focuses on the Glycated Albumin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Asahi Kasei Pharma
DIAZYME
Abnova
LifeSpan
Exocell
BSBE
Medicalsystem
Maccura
Leadman
Simes Sikma
NINGBO PUREBIO
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Glycated Albumin (Human)
Glycated Albumin (Animal)
Market Segment by Applications, can be divided into
Hospitals and Clinics
Laboratories
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glycated Albumin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glycated Albumin, with price, sales, revenue and global market share of Glycated Albumin in 2017 and 2018.
Chapter 3, the Glycated Albumin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glycated Albumin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Glycated Albumin market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Glycated Albumin sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
